We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Hyperbaric Oxygen Aids Chronic Wound Management

By HospiMedica International staff writers
Posted on 04 May 2015
A new study suggests that hyperbaric oxygen therapy (HBOT), as a means of treating a variety of wound types, may become an increasingly appropriate option for treatment. More...


A review of current evidence by researchers at the University of Exeter (United Kingdom) finds that using HBOT to treat tissue damage has been employed for almost 45 years. The results of the large number of prospective, retrospective, and randomized control trials show that using HBOT adjunctively with standard wound care improves healing, in particular for diabetic foot ulcers, and can result in a significant reduction in major amputations. Side effects of HBOT occur infrequently, but myopia, ear barotraumas, and (rarely) oxygen toxicity have been reported.

The physiological effects of HBOT treatment on wound tissue are profound and include the activation of immune cells, changes in cytokine production, and modulation of inflammatory and bactericidal mediators. HBOT also influences the biochemistry of whole cells, altering cell proliferation, angiogenesis, clotting, and tissue regeneration. The researchers clarified that the precise effects of HBOT on individual cell types and tissues are only beginning to be revealed in both animal and human studies. The study was published on April 24, 2015, in Chronic Wound Care Management and Research.

“As antibiotics become less available, and clinician time and complex dressings become more expensive, the use of HBOT as a means of treating a variety of wound types may become an increasingly appropriate option for treatment,” concluded lead author Prof. Paul Eggleton, PhD, and colleagues of the Institute of Biomedical & Clinical Science.

HBOT involves 100% pure oxygen delivered to a patient in an enclosed chamber at atmospheric pressure three times higher than normal air pressure. At those pressures, the body is able to incorporate more oxygen into blood cells, blood plasma, and cerebral-spinal and other bodily fluids; the increased oxygen absorption significantly enhances the body’s ability to aid in its own healing. In 1937 hyperbaric oxygen treatments were first used for decompression sickness, but it was not until 1956 that HBOT was used as a therapeutic aid in cardiopulmonary surgery.


Related Links:
University of Exeter



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.